Table 1. CD19 immunotherapy programs in development.
| Sponsor | Program | Class | MOA | Phase | Indications |
|---|---|---|---|---|---|
| Amgen |
Blinatomomab |
Bispecific scFv- CD19xCD3 (BiTE) |
T cell recruitment |
2 |
ALL, DLBCL |
| Sanofi-Aventis |
SAR3419 |
Antibody-drug conjugate |
Delivery of toxic payload |
2 |
DLBCL, ALL |
| Medimmune (AstraZeneca) |
MEDI-551 |
Glyco-engineered antibody |
Enhanced ADCC |
2 |
DLBCL, CLL, MS |
| Montefiore Medical Center |
Combotox |
scFv immunotoxins (CD19, CD22) |
Delivery of toxic payload |
1 |
ALL |
| NCI |
DT2219ARL |
Bispecific immunotoxin- CD19/CD22 |
Delivery of toxic payload |
1 |
B cell malignancies |
| Morphosys/Xencor |
MOR-208/Xmab5574 |
Fc engineered antibody |
Enhanced ADCC |
1 |
CLL |
| Xencor/Amgen |
XmAb-5871 |
Fc engineered antibody |
B cell inhibition via CD32B |
1 |
RA, SLE |
| Bristol-Myers Squibb |
MDX-1342 |
Glyco-engineered antibody |
Enhanced ADCC |
1 (on hold) |
CLL, RA |
| NCI |
CD19-CAR |
Chimeric antigen receptor (CAR) |
Engineered T cells (CD28) |
1 |
NHL, CLL |
| University of Pennsylvania |
CART19 |
Chimeric antigen receptor (CAR) |
Engineered T cells (4-1BB) |
1 |
CLL |
| Seattle Genetics |
SGN-19A |
Antibody-drug conjugate |
Delivery of toxic payload |
Preclinical |
|
| Affimed |
AFM11 |
Tetravalent bispecific antibody - CD19xCD3 |
T cell recruitment |
Preclinical |
|
| Glenmark |
GBR401 |
Naked antibody |
ADCC |
Preclinical |
|
| Macrogenics | CD19xCD3 DART | Bispecific scFv- CD19xCD3 (DART) | T cell recruitment | Preclinical |
ADCC, antibody-dependent cell-mediated cytotoxicity; ALL, acute lymphoblastic leukemia; BiTE, bispecifc T cell engager; CAR, chimeric antigen receptors; CD, cluster of differentiation; CLL, chronic lymphocytic leukemia; DART, dual-affinity re-targeting; DLBCL, diffuse large B cell lymphoma; MS, multiple sclerosis; NHL, non-Hodgkin lymphoma; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.